This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Lilly Diabetes Joins The American Diabetes Association As A National Sponsor Of The 2013 Tour De Cure® Cycling Event

INDIANAPOLIS, Nov. 27, 2012 /PRNewswire/ -- Today Lilly Diabetes announced it has joined the American Diabetes Association (Association) as a national sponsor of the 2013 Tour de Cure, the Association's annual nationwide cycling event that attracts more than 60,000 riders across 44 states. 

Lilly Diabetes has been an active supporter of the Association's efforts to Stop Diabetes® through support of key organizational initiatives including Living with Type 2 Diabetes, Everyday Wisdom™ kits, Safe at School® and diabetes camps. For more than 10 years Lilly Diabetes has been one of the largest supporters of diabetes summer camps in the U.S.

"Lilly Diabetes supports the Tour de Cure because at its heart, this event is a celebration of health, hope and community," said Enrique Conterno, president, Lilly Diabetes. "It also helps connect our employees with one another, and importantly, to connect them with the diabetes community we are dedicated to serving."

The Tour de Cure is one of the Association's signature fundraising events in which the organization's Stop Diabetes movement comes to life, encouraging participants to: Share, Act, Learn and Give. The Tour asks riders and donors to start a chain reaction by supporting its year-long series of cycling events across the country. Riders with type 1 or type 2 diabetes, as well as those who support them, can participate in courses of varying distances regardless of skill level. In 2013, Lilly Diabetes employees will participate as local and national team riders and will host local events and company-wide fundraising activities. The Lilly Foundation will match individual employee donations of $25 or more. In 2011, more than $18 million was raised to support the mission of the American Diabetes Association: to prevent and cure diabetes and to improve the lives of all people affected by diabetes.  

"Lilly Diabetes has truly been passionate in supporting the American Diabetes Association's mission and becoming part of our movement to Stop Diabetes," said Larry Hausner, CEO, American Diabetes Association. "We are excited to be working together again to help raise critical funds for diabetes through our Tour de Cure events nationwide."

Diabetes affects nearly 26 million children and adults in the United States – 8.3 percent of the U.S. population. It is estimated that an additional 79 million have prediabetes, putting them at risk for developing type 2 diabetes. Diabetes can lead to blindness, heart disease, stroke, kidney failure and amputations. Some common symptoms/signs of diabetes are extreme thirst, frequent urination, blurry vision, and tingling in the feet.

To register to ride, visit

About Lilly Diabetes Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and a continued commitment to providing real solutions–from medicines to support programs and more–to make lives better. For more information, visit

About Eli Lilly and Company Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers—through medicines and information—for some of the world's most urgent medical needs. Information about Lilly is available at

HI80116 11/2012 PRINTED IN USA ©Lilly USA, LLC 2012. All rights reserved.


1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 -0.41%
FB $117.81 -0.21%
GOOG $701.43 0.82%
TSLA $211.53 -4.96%
YHOO $36.94 2.61%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs